Abstract:
The present invention provides compositions and methods for identifying molecules in samples that bind to molecules associated with pathogenic agents (e.g., infectious agents). In certain aspects, the invention may be used to identify individuals that have been exposed to one or more pathogenic agent or have generated antibodies in response to one or more pathogenic agent. In other aspects, the invention is directed to the identification of molecules of one or more pathogenic agent that may be used to generate immune responses in other individuals.
Abstract:
A material comprising a porous support and a plurality of enzymes for the removal, decontamination or neutralization of hazardous chemicals such as OP compounds is disclosed. The material may be used on a variety of surfaces, including natural, synthetic and biological surfaces such as skin and other delicate membranes. Also disclosed is a process of making the material, kits and various methods and reactivation devices for reactivating the enzymatic activity of the material.
Abstract:
An apparatus and method for providing a forms system that preferably allows easy access to an an unlimited number of forms, a user to electronically sign a form, authentication of the data has not changed after the form has been electronically signed, data conversion, and external data importation into a data file. A further embodiment of the invention includes a method to incorporate signature capabilities into a form. Another aspect of the invention is consistent handling of data entered into forms by users (510).
Abstract:
A method and system preferably is for use in treating asthma patients by applying a score to the severity of the asthma based on answers to a series of questions. The system further preferably includes interactive education including what is asthma, how to lessen the likelihood of asthma attacks, and how to treat an asthma attack.
Abstract:
The present invention provides compositions and methods for identifying molecules in samples that bind to molecules associated with pathogenic agents (e.g., infectious agents). In certain aspects, the invention may be used to identify individuals that have been exposed to one or more pathogenic agent or have generated antibodies in response to one or more pathogenic agent. In other aspects, the invention is directed to the identification of molecules of one or more pathogenic agent that may be used to generate immune responses in other individuals.
Abstract:
Disclosed herein are 2-guanidinylimidazolidinedione compounds having the structural Formula A or B wherein R 1 and R 2 are each independently a hydrogen, halogen, alkyl, alkoxyl, amino, alkylamino or aralkyl, and wherein R 3 is an alkyl, cycloalkyl, heterocycloalkyl, acyl, aryl, heteroaryl, alkylaryl, sulfonyl, alkylsulfonyl, and pharmaceutically acceptable salts thereof, and methods of making thereof. Also disclosed are methods of treating, preventing, or inhibiting malaria with the 2-guanidinylimidazolidinedione compounds, and pharmaceutical compositions comprising the 2-guanidinylimidazolidinedione compounds, and kits.
Abstract:
Botulinum neurotoxins, the most potent of all toxins, induce lethal neuromuscular paralysis by inhibiting exocytosis at the neuromuscular junction. The light chains (LC) of these dichain neurotoxins are a new class of zinc-endopeptidases that specifically cleave the synaptosomal proteins, SNAP-25, VAMP, or syntaxin at discrete sites. The present invention relates to the construction, expression, purification, and use of synthetic or recombinant botulinum neutoroxin genes. For example, a synthetic gene for the LC of the botulinum neurotoxin serotype A (BoNT/A) was constructed and overexpressed in Escherichia coli. The gene product was purified from inclusion bodies. The methods of the invention can provide 1.1 g of the LC per liter of culture. The LC product was stable in solution at 4 DEG C for at least 6 months. This rBoNT/A LC was proteolytically active, specifically cleaving the Glu-Arg bond in a 17-residue synthetic peptide of SNAP-25, the reported cleavage site of BoNT/A. Its calculated catalytic efficiency kcat/Km was higher than that reported for the native BoNT/A dichain. Treating the rBoNT/A LC with mercuric compounds completely abolished its activity, most probably by modifying the cysteine-164 residue located in the vicinity of the active site. About 70 % activity of the LC was restored by adding Zn -free, apo-LC preparation. The LC was nontoxic to mice and failed to elicit neutralizing epitope(s) when the animals were vaccinated with this protein. In addition, injecting rBoNT/A LC into sea urchin eggs inhibited exocytosis-dependent plasma membrane resealing.
Abstract:
The present invention is directed to a system and method for providing researchers with a computer-assisted tool to evaluate, over a communications network, large electronic data sets stored on a remote server. The system allows the centralization of multiple data manipulation and analysis software modules co-located with the large data sets to reduce the amount of data from the data sets and software that has to be downloaded to a particular user's client computer. The system is designed to accommodate multiple researchers located at different geographic locations each of whom may have, with regard to the data, different scientific research objectives.
Abstract:
Disclosed herein is a pharmacophore model for antimalarial activity and methods of making and using thereof. The pharmacophore comprises two hydrogen bond acceptor (lipid) functions and two hydrophobic (aromatic) functions. The pharmacophore model was made using a test set of tryptanthrin compounds which exhibit antimalarial activity. Also disclosed are tryptanthrin compounds having greater solubility and bioactivity as compared to prior art tryptanthrin compounds and methods of making and using thereof. Also disclosed are methods of treating malaria in a subject.
Abstract:
A convertible isolation pod for an individual patient formed from sealable flexible plastic sheeting including an air intake grommet at the head end and an air exhaust grommet at the foot end of the pod each of the grommets being equipped with a Heimlich valve to provide unidirectional air flow within the pod where the air is filtered to remove contaminants.